Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines

NCT02324452 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT02324452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02324452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines
Lead sponsor
The Netherlands Cancer Institute
Phase
Not applicable
Overall status
Completed
Start date
March 31, 2015
Completion date
March 31, 2018
Enrollment
1,103 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms